1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Inclusion and exclusion criteria for patient selection
Inclusion CriteriaExclusion Criteria
Image-based evidence of a sidewall intracranial aneurysm interventionally treated only by using a FD in our institutionUnavailable aneurysm-related 4D PC MRI data
No history of related subarachnoid hemorrhage or other rupture cluesFusiform aneurysms without a well-defined ostium
No previous invasive treatment for target aneurysmUndesirable deployment of FD
Preprocedural acquisition of 4D PC MRI and 3D RA, and at least CE MR imaging or DSA follow-up with conclusive results at 6 or 12 monthsMissing all scheduled follow-ups
  • Note:—CE indicates contrast-enhanced.